[(2R,3S,4S,5R)-4-cyano-5-[4-(hexadecanoylamino)-2-oxopyrimidin-1-yl]-3-hydroxyoxolan-2-yl]methyl 8-(hydroxyamino)-8-oxooctanoate | 1236199-81-7

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘧啶核苷
• 英文名称: [(2R,3S,4S,5R)-4-cyano-5-[4-(hexadecanoylamino)-2-oxopyrimidin-1-yl]-3-hydroxyoxolan-2-yl]methyl 8-(hydroxyamino)-8-oxooctanoate
• CAS: 1236199-81-7
• 化学式: C₃₄H₅₅N₅O₈
• 分子量: 661.839
• InChiKey: DUJZZQGIVYIXSN-UAEGVTNASA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.3
• 重原子数：
  47
• 可旋转键数：
  26
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.76
• 拓扑面积：
  191
• 氢给体数：
  4
• 氢受体数：
  9

文献信息

• HYDROXAMIC ACID DERIVATIVES
  申请人：Purdue Pharmaceutical Products L.P.

  公开号：US20140066419A1

  公开（公告）日：2014-03-06

  The present invention is directed to a method of alleviating, relieving, altering, remedying, ameliorating, improving or affecting a neoplastic disease or an immune disease, the method comprising administering to a subject in need thereof an effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof: wherein P, Z, and m are defined herein above.
• US9096627B2
  申请人：——

  公开号：US9096627B2

  公开（公告）日：2015-08-04